M&A Archives - Pharmaphorum

Sanofi $750m acquisition gives it edge in flu vacccine market

July 11, 2017

Biotech’s Flublok is only FDA-approved cell-based flu jab

Sanofi $750m acquisition gives it edge in flu vacccine market

https://pharmaphorum.com/news/sanofi-buys-vaccine-biotech-protein-sciences/

CEO Meek looks to boost Ipsen with drug acquisitions

May 11, 2017

Could French biotech snap up remaining rights to pancreatic cancer drug?

CEO Meek looks to boost Ipsen with drug acquisitions

https://pharmaphorum.com/news/ipsen-looks-boost-rd-acquisitions/

Pfizer chief suggests no BMS bid – for now

May 4, 2017

Ian Read won’t quash rumours that his company Pfizer could swoop for vulnerable Bristol-Myers Squibb – but says it won’t make any major acquisitions in the

Pfizer chief suggests no BMS bid – for now

https://pharmaphorum.com/news/pfizer-ceo-suggests-bms-swoop-currently-risky/

GSK to search for blockbusters under new CEO Walmsley

April 26, 2017

Big projects are priority as threat from generic Advair looms.

GSK to search for blockbusters under new CEO Walmsley

https://pharmaphorum.com/news/gsk-search-blockbusters-new-ceo-walmsley/

Sucampo buys rare disease firm Vtesse

April 4, 2017

Sucampo gains rights to a drug for rare genetic disorder.

Sucampo buys rare disease firm Vtesse

https://pharmaphorum.com/news/sucampo-buys-rare-disease-firm-vtesse/

Astellas buys Ogeda after menopause drug impresses

April 3, 2017

Japanese pharma swoops after strong phase 2a results.

Astellas buys Ogeda after menopause drug impresses

https://pharmaphorum.com/news/astellas-buys-ogeda-menopause-drug-impresses/

J&J says $30bn Actelion buy on track

March 31, 2017

Deal set to close in Q2.

J&J says $30bn Actelion buy on track

https://pharmaphorum.com/news/jj-says-30bn-actelion-buy-track/

AZ’s Tagrisso gets full US approval in lung cancer

March 31, 2017

Phase 3 data confirmed its efficacy in patients with a certain mutation.

AZ’s Tagrisso gets full US approval in lung cancer

https://pharmaphorum.com/news/azs-tagrisso-gets-full-us-approval-lung-cancer/

Marathon sells Duchenne drug to PTC

March 16, 2017

PTC says it will make changes to the price after abandoned launch last month.

Marathon sells Duchenne drug to PTC

https://pharmaphorum.com/transversal-categories/rare-diseases/marathon-sells-duchenne-drug-ptc/

Trending

M&A

Sanofi $750m acquisition gives it edge in flu vacccine market

CEO Meek looks to boost Ipsen with drug acquisitions

Pfizer chief suggests no BMS bid – for now

GSK to search for blockbusters under new CEO Walmsley

Sucampo buys rare disease firm Vtesse

Astellas buys Ogeda after menopause drug impresses

J&J says $30bn Actelion buy on track

AZ’s Tagrisso gets full US approval in lung cancer

Marathon sells Duchenne drug to PTC

Inhalation and Respiratory Drug Products Summit

THET Annual Conference 2017

Clinical Trial Supply East Coast 2017

Livongo’s diabetes solution impresses in latest study

Vifor’s hyperkalaemia drug Veltassa approved in Europe

New 3-year data supports Kite ‘cure’ hopes for CAR-T

Daiichi Sankyo anticoagulant gains EU label boost

Teva’s Cinqaero to challenge Nucala after clearing NICE

The most notable digital health trends of 2017 so far

Europe has untapped medical innovation – but needs high speed connections to make it work

Healthcare’s hype cycle: which technologies will stay the course?

Looking back, looking forward – Janssen’s 60 years on the psychiatry horizon

What HCPs say about Roche’s breast cancer drug

Search

Advanced Search

Trending

M&A